Nanomedicine for the management of rheumatoid arthritis: current status and prospective therapeutic approaches

Nanotechnology has rapidly become a viable instrument for investigating innovative methods, ranging from properly identifying many disorders to treating intricate medical situations. Due to their adjustable surface qualities and similar size dimensions, custom-designed nanoparticles can now interact with cellular targets and diverse diseases more effectively. The primary objective of medicine distribution is to guarantee that pharmaceuticals are supplied only to the necessary areas, minimizing side effects and unintended consequences. Rheumatoid Arthritis (RA) is a persistent inflammatory condition that results in the gradual deterioration of bone as well as cartilage, resulting in significant disability, reduced life, and elevated mortality rates. Advanced treatment for RA notably decreased the disease’s progression and enhanced the life quality for numerous individuals. Conversely, individuals can occasionally achieve remission of their illnesses and maintain them without the continuous need for immunosuppressants. Many patients either develop tolerance to or exhibit non-responsiveness to existing treatments. Consequently, novel pharmaceutical strategies for the treatment of RA remain necessary. In contrast to conventional pharmaceuticals, nanocarriers are engineered to deliver therapy directly to the joint inflammation site, thus circumventing systemic and adverse side effects. Drugs previously deemed excessively hazardous for systemic administration are presently undergoing re-evaluation by scholars. This article summarizes contemporary nanotechnology methods for managing RA and discusses potential advancements in nanotherapeutic approaches.